Topical finasteride + minoxidil spray is intended for use by MEN ONLY and should NOT be used by women or children.
Topical finasteride + minoxidil spray is a prescription medication used for the treatment of male pattern hair loss (androgenetic alopecia). It is a treatment alternative to oral finasteride that has been shown in research studies to be safe and effective. Unlike oral finasteride, topical finasteride + minoxidil spray is a compounded product and has not been approved by the FDA. The use of topical finasteride to treat hair loss has been as comprehensively studied as oral finasteride. While research has shown that serum DHT levels decrease while using topical finasteride, the systemic side effects (e.g., sexual dysfunction) typically associated with oral finasteride were not reported in the studies of topical finasteride.
Do not use other topical minoxidil products while you are using the Topical finasteride 0.3% + minoxidil 6% spray.
Do not allow individuals who are pregnant or breastfeeding, individuals who have the potential to become pregnant, or children handle this medication. Do not allow any of these individuals to come into contact with the treatment site (your scalp) after the medication has been applied. If they do, they should immediately clean the site of contact on their skin with soap and water.
Topical finasteride + minoxidil spray is intended for use by MEN ONLY and should NOT be used by women or children.
Topical finasteride + minoxidil spray is a prescription medication used for the treatment of male pattern hair loss (androgenetic alopecia). It is a treatment alternative to oral finasteride that has been shown in research studies to be safe and effective. Unlike oral finasteride, topical finasteride + minoxidil spray is a compounded product and has not been approved by the FDA. The use of topical finasteride to treat hair loss has been as comprehensively studied as oral finasteride. While research has shown that serum DHT levels decrease while using topical finasteride, the systemic side effects (e.g., sexual dysfunction) typically associated with oral finasteride were not reported in the studies of topical finasteride.
Do not use other topical minoxidil products while you are using the Topical finasteride 0.3% + minoxidil 6% spray.
Do not allow individuals who are pregnant or breastfeeding, individuals who have the potential to become pregnant, or children handle this medication. Do not allow any of these individuals to come into contact with the treatment site (your scalp) after the medication has been applied. If they do, they should immediately clean the site of contact on their skin with soap and water.
Topical finasteride + minoxidil spray is intended for use by MEN ONLY and should NOT be used by women or children.
Topical finasteride + minoxidil spray is a prescription medication used for the treatment of male pattern hair loss (androgenetic alopecia). It is a treatment alternative to oral finasteride that has been shown in research studies to be safe and effective. Unlike oral finasteride, topical finasteride + minoxidil spray is a compounded product and has not been approved by the FDA. The use of topical finasteride to treat hair loss has been as comprehensively studied as oral finasteride. While research has shown that serum DHT levels decrease while using topical finasteride, the systemic side effects (e.g., sexual dysfunction) typically associated with oral finasteride were not reported in the studies of topical finasteride.
Do not use other topical minoxidil products while you are using the Topical finasteride 0.3% + minoxidil 6% spray.
Do not allow individuals who are pregnant or breastfeeding, individuals who have the potential to become pregnant, or children handle this medication. Do not allow any of these individuals to come into contact with the treatment site (your scalp) after the medication has been applied. If they do, they should immediately clean the site of contact on their skin with soap and water.
Minoxidil 6% + Dutasteride 0.1% + Biotin 0.2% + Caffeine 0.5% + Melatonin 0.1% topical solution is a compounded preparation intended for use in adult males diagnosed with androgenetic alopecia (male pattern hair loss). The safety and efficacy of this formulation have not been established in women or pediatric populations. Minoxidil acts as a peripheral vasodilator that promotes follicular stimulation and prolongation of the anagen phase. Dutasteride is a dual 5-alpha reductase inhibitor that reduces dihydrotestosterone (DHT) levels in scalp tissue. Biotin supports keratin infrastructure, caffeine has been reported to stimulate follicular activity and counteract DHT-related suppression in vitro, and melatonin may assist in regulating the hair growth cycle through antioxidant and chronobiological mechanisms.
This formulation is a compounded topical preparation and the specific combination and concentrations have not been approved by the U.S. Food and Drug Administration (FDA) or the Drug Regulatory Authority of Pakistan (DRAP). Its use constitutes off-label therapy and should be undertaken under medical supervision. The product is contraindicated in individuals with known hypersensitivity to any of its components, in women, particularly during pregnancy or lactation, and in pediatric patients. Dutasteride is contraindicated in women who are pregnant or may become pregnant due to the potential risk of abnormalities in a male fetus. Individuals who are pregnant, breastfeeding, or of childbearing potential should avoid handling the medication and avoid contact with treated areas; in case of accidental exposure, the affected area should be washed immediately with soap and water.
Concomitant use with other topical minoxidil-containing products is not recommended. Systemic absorption of dutasteride may occur with topical administration; therefore, systemic adverse effects cannot be completely excluded. Caution is advised in patients with underlying cardiovascular conditions. Potential adverse reactions may include scalp irritation, erythema, dryness, pruritus, temporary increased hair shedding during initial use, headache, and rarely systemic effects associated with 5-alpha reductase inhibition. Discontinuation and medical evaluation are recommended if significant adverse reactions occur.
Ideal for Early-Stage Thinning
